David B. Stagg

Degradation of proteins by PROTACs and other strategies

Breast cancer

Advances in targeted degradation of endogenous proteins

Triple-negative breast cancer molecular subtyping and treatment progress

Bardoxolone conjugation enables targeted protein degradation of BRD4

Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Targeting Nuclear Receptors with PROTAC degraders

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

PROTAC targeted protein degraders: the past is prologue

Male breast cancer: a disease distinct from female breast cancer

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

Targeted protein degradation by PROTACs

Plasticity in binding confers selectivity in ligand-induced protein degradation

Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway

Induced protein degradation: an emerging drug discovery paradigm

Waste disposal—An attractive strategy for cancer therapy

Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Small‐Molecule‐Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging

Small‐Molecule‐Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging